Protagonist Therapeutics Inc

PTGX remains in a Stage 2 advancing uptrend confirmed by a recent Momentum Breakout, but the stock is extended and extremely overbought. A speculative approach favors waiting for a shallow pullback into the rising 9/21 EMA support zone before engaging. Stalk for a clearer entry on structural support while monitoring for distribution risk.

• ↑Institutional ownership ~98.6%, reflecting high hedge fund backing.
• ↑Q1 revenue $56.4 M, above estimates, and collaboration revenue rising.
• ↓Net loss $114.7 M and negative profitability factors persist.